Production, Purification, and Characterization of a Novel Cysteine-Rich Anticoagulant from the Medicinal Leech and the Functional Role of Its Disulfide Bonds
Basic science / preclinical published in Biomolecules (2025)
Abstract
The saliva of the medicinal leech Hirudo medicinalis contains a wide range of biologically active compounds, including multiple anticoagulants. Previously, we identified a novel cysteine-rich anticoagulant protein (CRA) from leech saliva and produced it recombinantly in Escherichia coli, demonstrating its potential as a basis for new anticoagulant drugs. In this study, we developed an optimized procedure for scalable production and purification of recombinant CRA. The purified protein was analyzed for common contaminants originating from E. coli, such as endotoxins, bacterial proteins, and DNA, and its anticoagulant properties were evaluated using standard clotting assays. Across three independent experiments, the yield of purified CRA ranged from 3.7 to 5.5 mg per liter of bacterial culture, with impurity levels per milligram of protein ranging from 7.1-31.2 ng of bacterial proteins, 1.2-15.1 ng of DNA, and 60-1445 EU of endotoxins. The purified CRA displayed electrophoretic and chromatographic homogeneity and retained strong anticoagulant activity. Additionally, a truncated form of CRA lacking the C-terminal region was produced and characterized. This variant lost membrane affinity and showed altered activity profiles, with higher thrombin time activity but reduced prothrombin time and activated partial thromboplastin time activities compared with the full-length protein.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Production, purification, and characterization of a novel cysteine-rich anticoagulant (CRA) from Hirudo medicinalis salivary secretions — a distant homolog of antistasin. The study describes recombinant expression in E. coli, refolding, and clotting-assay verification, with structural analysis of disulfide bonds essential for activity.
Por qué esto importa para la hirudoterapia
El estudio reporta un procedimiento optimizado para producir y purificar una proteína anticoagulante recombinante rica en cisteína a partir de la saliva de la sanguijuela medicinal Hirudo medicinalis en Escherichia coli, incluyendo la evaluación de contaminantes y la caracterización mediante ensayos de coagulación. Encontró rendimientos de proteína purificada de 3,7 a 5,5 mg por litro de cultivo, midió rangos de impurezas para proteínas bacterianas, ADN y endotoxinas, homogeneidad electroforética y cromatográfica, y actividad anticoagulante retenida; una variante truncada en el extremo C-terminal perdió afinidad por membranas y mostró perfiles de actividad alterados en el tiempo de trombina, tiempo de protrombina y tiempo de tromboplastina parcial activada. Esto es directamente relevante para ASH porque se refiere a un anticoagulante de la saliva de la sanguijuela y su potencial como candidato para el desarrollo de fármacos. La advertencia es que el trabajo es bioquímico y preclínico, sin datos terapéuticos en animales o humanos y sin evaluación de la terapia con sanguijuelas vivas.
Citación
Production, Purification, and Characterization of a Novel Cysteine-Rich Anticoagulant from the Medicinal Leech and the Functional Role of Its Disulfide Bonds.
Manuvera VA et al. · Biomolecules, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026